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Abstract: Primary progressive aphasia (PPA) is a neurodegenerative disease of insidious onset 
presenting with progressive isolated loss of language function, without signiﬁ  cant impairment in 
other cognitive domains. Current diagnostic criteria require the language dysfunction to remain 
isolated for at least two years, and to remain the salient feature as the disease progresses, usually 
to involve other domains such as behavior, executive functions, and judgment. Although PPA 
in its early stages can usually be differentiated from probable Alzheimer’s disease (PRAD) 
and the behavioral variant of frontotemporal lobar degeneration by the absence of signiﬁ  cant 
changes in memory and behavior, and the preservation of activities daily living, progression of 
the disease often leads to deﬁ  cits more consistent with the latter. Underlying etiologies remain 
heterogeneous: the neuropathological characteristics associated with frontotemporal lobar 
degeneration, cortocobasal degeneration, and motor neuron disease are usually found. There 
is a strong genetic susceptibility with afﬂ  iction of ﬁ  rst-degree relatives with similar disease 
in up to 40 to 50% in some series. Pathogenic mutations in genes coding for the proteins tau 
and progranulin have been isolated. These are leading to a better understanding of the neuro-
pathological mechanisms and hopefully targeted disease-modifying therapy. Current therapy is 
limited to improving mood symptoms and targeting behavior changes as they develop. Referral 
to specialized centers where speech therapy, counseling, and education for both patient and 
caregiver are available may be helpful.
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Introduction
Primary progressive aphasia (PPA) is a clinical syndrome deﬁ  ned by the insidious 
onset and progressive dissolution of language skills (Mesulam 1982, 2001, 2003). 
Although additional cognitive symptoms may emerge later in the course of illness, 
deﬁ  cits must be grossly conﬁ  ned to the area of language for at least 2 years to fulﬁ  ll 
the criteria for a diagnosis of PPA. The ﬁ  rst description of the syndrome is attributed 
to Mesulam (1982), but reports of similar clinical ﬁ  ndings have been in the literature 
for over 100 years (Mesulam and Weintraub 1992).
The neuropathological underpinnings of PPA are varied (see section on neuro-
pathology), but the most frequent etiology may be one of the pathological processes 
leading to frontotemporal lobar degeneration (FTLD). As deﬁ  ned by Neary et al (1998), 
FTLD may present clinically as either a behavioral disorder, called frontotemporal 
dementia (FTD) or occasionally behavioral variant FTD (bv-FTD), or one of two so 
called language disorders: semantic dementia (SD) and progressive non-ﬂ  uent aphasia 
(PNFA). These disorders and their relation to PPA will be discussed.
Differential diagnosis
PPA can be usually be differentiated from the clinical syndrome of Probable 
Alzheimer’s Disease (PRAD) by the relative preservation of memory, and from FTD 
by the relative sparing of frontal lobe functions and appropriateness of behavior.
Although the language disorder in PPA may interfere with the ability to memorize 
word lists or solve reasoning tasks, the patient typically has no difﬁ  culty recalling daily Neuropsychiatric Disease and Treatment 2007:3(6) 746
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events or behaving with good judgment, indicating that 
explicit memory, executive functions and social skills remain 
intact.
Clinical presentation and evolution
By deﬁ  nition, language disturbances are the most salient 
feature in the early clinical picture of PPA. In fact, the 
diagnostic criteria require at least two years of relatively 
isolated language impairment with generally intact function-
ing in other cognitive abilities such as episodic memory, 
visuospatial skills, reasoning, and comportment (Mesulam 
and Weintraub 1992). It may often be difﬁ  cult to conﬁ  rm 
normal function in other cognitive when signiﬁ  cant language 
deﬁ  cits are present. Modiﬁ  cation of standard testing para-
digms to reduce their dependence on language skills can 
be useful (Wicklund et al 2004). Deﬁ  cits in other cognitive 
domains eventually emerge after the initial few years, but the 
language dysfunction remains the most salient feature and 
advances most rapidly, throughout the course of the illness 
(Mesulam 2003). Primary progressive aphasia is distinct 
from states of pure progressive dysarthria or phonologi-
cal disintegration where the articulation rather than usage 
of words becomes disrupted. Patients with PPA may also 
show mild ideomotor (usually buccofacial) apraxia, dyscal-
culia, disinhibition, and constructional deﬁ  cits (Joshi et al 
2003). These additional symptoms indicate a progression 
or spread of dysfunction to prefrontal and parietal cortices 
immediately adjacent to the language network. The term 
PPA-plus has been proposed to designate this advancing 
state (Mesulam 2001).
PPA may be considered a syndromic entity that results 
from any one of a number of initially focal neuropathological 
processes, beginning in the language network (Kertesz et al 
1994) (see section VI). With progression, these processes lead 
to more generalized clinical involvement resulting in recog-
nizable diseases that can additionally include the behavioral 
variant of frontotemporal lobar degeneration, corticalbasal 
degeneration (CBD) (Kertesz et al 1994; Ikeda et al 1996; 
Gorno-Tempini, Murray et al 2004; McMonagle et al 2006), 
and even amyotrophic lateral sclerosis (ALS) (Bak et al 
2001; Caselli et al 1993). Occasionally, Alzheimer’s disease 
(Pogacar and Williams 1984; Greene et al 1990, 1996) or 
Creutzfeldt-Jakob disease (Shuttleworth et al 1985; Mandell 
et al 1989; Ghorayeb et al 1998) is diagnosed. Although 
the neurological examination may be completely normal 
in the early stages, the presence of increased muscle tone, 
apraxia, or subtle signs of parkinsonism may be harbingers 
of what is to follow. As PPA progresses, it blends into the 
symptomatology of FTD, CBD or the motor neuron disease 
of ALS so that signiﬁ  cant dysarthria, primitive reﬂ  exes 
(particularly from the dominant hemisphere), hemiparesis, 
tremor, rigidity, bradykinesia or akinesia, alien hand phe-
nomenon, hemisensory deﬁ  cits, and fasciculations may be 
observed. Regardless of the underlying etiology, the unique 
feature of PPA is the initial predominance of the language 
deﬁ  cit and the corresponding initial selectivity of the neu-
rodegeneration for the language network.
Subtypes of PPA
Although he included detailed descriptions of the nature and 
evolution of the aphasia in each of his original 6 patients, 
Mesulam did not attempt to divide PPA into subgroups. 
Instead, he emphasized the remarkable selectivity that the 
disease seemed to demonstrate for the language network, 
regardless of the exact nature of the aphasia. Attempts to use 
traditional aphasia subtypes such as Broca’s, Wernicke’s, 
or Conduction Aphasia to classify language deﬁ  cits in PPA 
have not been entirely successful (Clark et al 2005; George 
and Mathuranath 2005). Unlike aphasia due to stroke 
where the lesions tend to be more severe in a focal brain 
region, in PPA the degeneration is less severe and more 
widespread and the clinical symptoms are quite variable 
(Thompson et al 1997) and most do not conform to the 
traditional anatomical patterns based on stroke subjects. 
These difﬁ  culties notwithstanding, with the increasing 
number of cases being evaluated in detail, it has been pos-
sible for many groups to propose classiﬁ  cation systems. 
These systems vary considerably in their complexity. The 
simplest of these follows Mesulam’s contention that PPA is 
a single disease entity showing a smooth clinical spectrum 
spread over a continuum, with ﬂ  uent, grammatically intact, 
but content poor speech reminiscent of Wernike’s aphasia 
at one extreme, and non-ﬂ  uent, agrammatic, effortful, and 
content rich speech, more in keeping with Broca’s aphasia, 
at the other. Other investigators have proposed classiﬁ  ca-
tions based on at least three (Snowden et al 1992; Grossman 
and Ash 2004), and up to six (Kertesz et al 2003) categories. 
All present with and are characterized by the presence of 
anomia, and differentiated on the basis of measures of 
ﬂ  uency, the presence or absence of logopenia or word 
ﬁ  nding difﬁ  culties, and loss of word meaning or compre-
hension. Part of the difﬁ  culty in classifying presentations 
of PPA lies in the nature of the disease process in any given 
individual, which begins with a distinct ‘anatomy of disease 
onset’ and evolves according to a variable ‘progression 
trajectory’(Mesulam 2001).Neuropsychiatric Disease and Treatment 2007:3(6) 747
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It is not surprising that there exists some controversy 
concerning the most natural approach to categorizing the 
progressive aphasias. An optimal classification system 
applicable during life would be clinically relevant, betray 
the underlying disease process, and predict its evolution. 
Classifying the presentation helps localize the brain areas 
initially affected and, as the extent of the pathology progresses 
to involve neighboring systems, predicts the manifestations to 
follow.
In addition to the clinical criteria for the diagnosis of the 
behavioral presentation of FTD (bvFTD), Neary et al (1998), 
in their description of the possible clinical entities resulting 
from the pathological processes involved in FTLD, also 
distinguished two forms of language presentations: PNFA 
and SD. The term SD (Hodges et al 1992; Snowden et al 
1992; Neary et al 1998) was introduced to designate a unique 
syndrome in which a prominent ﬂ  uent aphasia with impaired 
comprehension emerges in the presence of prominent deﬁ  cits 
of visual recognition (agnosia). There is also belief that 
patients with SD can be shown to have circumscribed deﬁ  cits 
in semantic knowledge that contributes to their language dif-
ﬁ  culties (Snowden et al 1989; Hodges et al 1992). In clinical 
practice, this term has also been used to denote patients with a 
ﬂ  uent aphasia and verbal comprehension deﬁ  cits, even in the 
absence of visual processing deﬁ  cits. The term PNFA denotes 
patients with a non-ﬂ  uent aphasia and relatively preserved 
comprehension. Patients with PNAF and non-agnostic SD 
would also fulﬁ  ll criteria for a diagnosis of PPA. Because 
ﬂ  uency and grammaticism are the most clinically obvious 
differences between these two presentations, the term ‘ﬂ  uent 
PPA’ is sometimes equated to SD, and ‘non-ﬂ  uent PPA’ or 
‘agrammatic PPA’ to PNFA.
There has evolved an extensive literature comparing 
various subtypes of PPA in terms of the associated cogni-
tive and behavioral manifestations, structural and functional 
imaging ﬁ  ndings, and pathological underpinnings. Although 
a complete analysis of this literature is beyond the scope 
of this short review, key references will be made within 
relevant sections.
Gorno-Tempini, Dronkers et al (2004) described three 
subtypes of PPA, logopenic, agrammatic, and semantic, 
which correspond to distinctive patterns of brain atrophy. 
The logopenic variant is characterized by word-ﬁ  nding 
difﬁ  culties and decreased output, but relatively preserved 
syntax, grammar and comprehension. The agrammatic 
subtype, which is similar to the Neary et al (1998) criteria 
for the PNFA subtype of FTLD, is characterized by labored 
speech, agrammatism in production and/or comprehension, 
variable degrees of anomia, and phonemic paraphasias, in 
the presence of relatively normal word comprehension. The 
semantic variant is characterized by ﬂ  uent, grammatically 
correct speech, loss of word and object meaning, surface 
dyslexia and relatively preserved syntactic comprehension 
skills.
Loss of semantic memory and non-verbal deﬁ  cits in pro-
gressive aphasias were recognized initially by Warrington 
(1975). Deﬁ  cits of this kind are found in patients with SD 
(Snowden et al 1989; Hodges et al 1992). Debate about the 
ability to conﬁ  rm such deﬁ  cits in patients with language 
impairment has generated experimental paradigms that rely 
more on pictures, such as the ‘Pyramids and Palm Trees’ 
test (Howard and Patterson 1992), which assesses semantic 
associations non-verbally, tasks involving coloring of black 
and white line drawing of well known animals, and on tests 
matching environmental sounds to target pictures (Bozeat 
et al 2000).
In a comprehensive review of the literature, Grossman 
and Ash (2004) conclude that there is enough evidence to 
support the notion that PPA can in fact be divided into PNFA 
and SD (without visual agnosia). Their conclusions are based 
on an analysis of both the linguistic proﬁ  les and imaging 
characteristics of these variants. In a novel data driven 
hierarchical cluster analysis of the clinical characteristics 
of patients with PPA, Knibb et al (2006) also conﬁ  rmed the 
importance of two major presentations that roughly conform 
to these variants.
That PPA can present in ﬂ  uent or non-ﬂ  uent forms is 
clear; however, Mesulam has argued that the use of the term 
SD, to denote the ﬂ  uent form of PPA is not entirely accurate 
because it should, as deﬁ  ned by Neary (1998), include a 
visual associative agnosia, and is therefore not strictly a 
language disorder (Weintraub et al 1990; Mesulam 2001, 
2003). He has advocated the use of the term SD only in 
the context of demonstrable agnosia and suggested that SD 
must represent an afﬂ  iction of at least two separate systems 
(Mesulam 2001). In response, Adlam et al (2006) have 
described seven patients who met Mesulams criteria for the 
diagnosis of PPA (Mesulam 2001, 2003), but additionally 
had subtle non-verbal deﬁ  cits in semantic memory when 
these were expressly sought using sensitive paradigms that 
they developed. Although there still remains much debate 
concerning the use of the term SD to describe what is initially 
perceived as a ‘pure’ language disorder, its historic impact 
and commonplace usage has made it important to discuss.
The US National Alzheimer’s Coordinating Center 
(NACC), in an effort to standardize data collection and Neuropsychiatric Disease and Treatment 2007:3(6) 748
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diagnostic criteria for Alzheimer’s disease and related 
dementias, has collated complete lists of diagnostic criteria, 
with relevant references. In their treatment of the progressive 
aphasias, they recommend the use of the criteria deﬁ  ned by 
Mesulam, but further subcategorize according to the Neary, 
into PNFA and SD, with special attention to the presence 
or absence of agnosia associated with SD, and add a fourth 
category ‘other’ that includes logopenic, anomic, transcortical, 
word deafness, syntactic comprehension, and motor speech 
disorder (https://www.alz.washington.edu/NONMEMBER/
UDS/DOCS/VER1_2/pubguide.pdf, p 54–8).
Behavior, emotion, and mood
Although not a salient feature of PPA in its early stages 
(Weintraub et al 1990), the emergence of behavioral 
changes generally signal progression of the disease, as has 
been quantiﬁ  ed using various measures including Kertesz’ 
Frontal Behavioral Inventory (FBI) (Kertesz et al 1997; 
Marczinski et al 2004) and the NPI-Q (Kaufer et al 2000; 
Banks and Weintraub, in press). The types of behavioral 
changes that emerge seem to depend on the aphasia variant at 
hand and reﬂ  ect progression of the disease from the variants 
epicenter to adjacent areas. In this way, patients with SD were 
found to develop apathy and changes in food preferences, 
while patients with a non-ﬂ  uent form exhibited later onset 
irritability (Snowden et al 1992). Stereotypic behavior, 
changes in eating preference, disinhibition and reduced social 
awareness can also be demonstrated as earlier features of SD 
(Bozeat et al 2000).
Depression in PPA is being recognized (Medina and 
Weintraub, in press), perhaps as a reaction to their ongoing 
losses and preserved insight (Eslinger et al 2005). Depressive 
symptoms such as irritability seem to remain present for 
longer periods (Kertesz et al 2000).
Imaging
Patients with PPA typically show gyral atrophy of the 
left hemisphere involving frontal, temporal, insular and 
parietal components of the language network (Mesulam 
and Weintraub 1992; Rosen, Kramer et al 2002). In PPA, 
metabolic abnormalities tend to parallel predominant lan-
guage dysfunction, in that non-ﬂ  uent patients have reduced 
metabolism in left frontal areas, including the insula, while 
ﬂ  uent patients with impairments in comprehension tend to 
have reduced left temporal metabolism (Abe et al 1997; 
Rosen, Gorno-Tempini et al 2002; Nestor et al 2003).
With regard to specific subtypes, Gorno-Tempini, 
Dronkers et al (2004) used voxel-based morphometry (VBM) 
to demonstrate the differential involvement of distinct brain 
regions in the three variants that they deﬁ  ned clinically. In 
PNFA, atrophy involved the left inferior frontal and insular 
cortex. In their semantic variant, the anterior temporal 
regions were preferentially affected, while in the logopenic 
patients, involved areas were the left posterior temporal and 
inferior parietal cortices. The same group also demonstrated 
a relationship between the appearance of mutism in PNFA 
and further atrophy of the pars opercularis and extension into 
the left basal ganglia (Gorno-Tempini et al 2006). Bilateral 
temporal atrophy, left greater than right, has also previ-
ously been demonstrated in SD by Mummery et al (2000) 
and Rosen, Gorno-Tempini et al (2002). In their report, 
Mummery et al (2000) also demonstrated a relationship 
between the degree of semantic impairment and the extent 
of left anterior temporal lobe atrophy. Rosen, Kramer et al 
(2002) had also previously demonstrated similar changes 
in their report of 3 patients with variants of PPA. In their 
combined PET and VBM analysis of patients with PNFA, 
Nestor et al (2003) demonstrated hypometabolism in the left 
anterior insula/frontal opercular region, and atrophy in the 
left peri-Sylvian region. PET and SPECT imaging may be 
able to differentiate the underlying etiology of PNFA (Nestor 
et al 2007). When only Alzheimer’s disease-like changes 
(see pathology section below) were found at autopsy, nuclear 
imaging during the initial diagnostic workup more consis-
tently demonstrated hypoperfusion deﬁ  cits in the posterior 
temporoparietal association cortex, a pattern very speciﬁ  c 
for PRAD, in contrast to changes in the left anterior insula/
frontal opercular region noted above that are associated with 
‘FTD-spectrum’ pathology (Nestor et al 2007).
Although often present with aphasia, the development of 
apraxia of speech suggests involvement beyond the language 
network. Using VBM, Josephs et al (2006) demonstrated 
that the presence of non-ﬂ  uent aphasia was associated with 
anterior peri-sylvian atrophy, while the presence of speech 
apraxia followed changes in left premotor and supplemental 
motor cortex.
Despite marked left hemisphere dysfunction in 
non-ﬂ  uent PPA, the metabolic state of the contralateral 
right hemisphere tends to remain within the normal range 
(Chawluk et al 1986; Tyrrell et al 1990). When asked to 
identify homonyms or synonyms in the course of functional 
MRI (fMRI) experiments, PPA patients (ﬂ  uent and non-
ﬂ  uent) and controls activate the same components of the 
language network (Sonty et al 2003). However, in contrast 
to neurologically intact subjects, the PPA patients display 
aberrant (possibly compensatory) activations within Neuropsychiatric Disease and Treatment 2007:3(6) 749
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regions of the brain outside of the classic language network 
(Mummery et al 1999; Sonty et al 2003). Using fMRI 
and a grammatically complex sentence comprehension 
paradigm, Cooke et al (2003) showed that patients with 
PNFA produce less activation within the ventral portion 
of the inferior frontal cortex, an area felt to be crucial to 
the processing of complex sentences. They further postu-
late that this interruption of a putative large-scale neural 
network for sentence comprehension (Cooke et al 2006) 
forms the basis for the complex grammatic comprehension 
deﬁ  cits seen in these patients.
Neuropathology
Generally, as a group, the various neuropathological 
ﬁ  ndings associated with PPA and FTD have been called 
frontotemporal lobar degeneration (FTLD) (Neary et al 
1998). These are not uniform and their characterization 
is changing as a result of improvements in genetics and 
staining techniques. Speciﬁ  cally, the neuropathological 
ﬁ  ndings are a function of a number of possible underlying 
etiologies. At autopsy, the most uniform ﬁ  nding is that of 
focal degeneration, which is usually found preferentially 
and more intensely in language areas, and characterized by 
neuronal loss, gliosis, and spongiform changes involving the 
superﬁ  cial cortical layers. Cortex may also contain occasional 
ballooned neurons, called Pick cells. Staining with silver 
and newer histochemical stains for either the microtubule 
associated protein tau (MAPT or simply tau) or ubiquitin can 
reveal neuronal and glial inclusions in a pattern particular to 
the exact neurpathological process at hand. Pick bodies are 
argyrophilic (silver staining) spherical neuronal inclusions 
diagnostic of Pick’s disease. Similar neuronal inclusions may 
only be visible with tau immunostaining, thus deﬁ  ning the 
underlying disorder as a ‘tauopathy’ such as in certain forms 
of FTD, CBG, and progressive supranuclear palsy (PSP). 
Other non-argyrophilic tau negative inclusions may stain 
only for ubiquitin, as is found when FTD is associated with 
motor neuron disease. When ubiquitin inclusions are found 
in the absence of clinical motor neuron disease, the ﬁ  nding 
is termed FTD-MND type. FTD associated with ubiquitin 
inclusions is also referred to as FTLD-U. When no inclusions 
can be found, the pathology is often referred to as dementia 
lacking distinctive histopathology (DLDH) (Knopman et al 
1990), a diagnosis that is becoming increasingly scarce as 
immunohistochemical techniques are reﬁ  ned (Mackenzie 
et al 2006). Although these pathological ﬁ  ndings are quite 
distinct in their staining characteristics and even genetic 
underpinnings (see below), they are generally considered 
as representing the ‘FTD-spectrum’ of pathologies that are 
most frequently found in FTLD.
Occasionally extracellular plaques and neuronal neurﬁ  -
brillary tangles characteristic of Alzheimer’s disease are 
found. In many instances their distribution is unusual and 
follows a more frontotemporal pattern, rather than the classic 
temporparietal one, resulting in brains with a macroscopic 
appearance more in keeping with FTLD (Knibb et al 2006).
A recent clinicopathological study (Forman et al 2006) 
suggests that tau pathology is more frequently associated 
with extrapyramidal disorders while FTLD-U manifests 
more frequently as bv-FTD, PPA, and motorneuron disease. 
In their cluster analysis, Knibb et al (2006) found AD-like 
changes accounted for roughly one third cases of ﬂ  uent 
and non-ﬂ  uent PPA. They also noted that tau-based disease 
was more common than FTLD-U in the non-ﬂ  uent cluster 
(43 vs 17%), while in the ﬂ  uent group this trend was reversed 
(13 vs 53%).
Genetics
The not uncommon familial association of PPA and FTD 
supports a genetic link between them. Some 38 to 50% of 
clinical FTD cases appear to be familial (Stevens et al 1998; 
Grasbeck et al 2005). Countless kindred have been described 
that demonstrate segregation of a disease in an autosomal 
dominant pattern of inheritance. The clinical disease itself 
is usually FTD, but can include parkinsonism, motor neuron 
disease, or progressive aphasia, even in the same family. In 
some families, a mutation in the gene coding for tau (found 
on chromosome 17q21) can be demonstrated. Postmortem 
analysis usually reveals tau pathology.
More recently, a genetic cause of FTD with tau-negative 
ubiquinated inclusions (FTLD-U) was traced to progranulin 
(PRGN) gene mutations, also found on chromosome 17q21 
(Cruts et al 2006; Baker et al 2006). The mutations cause a 
null allele and a reduction in the level of functional PRGN 
protein. Replacement of this missing protein may represent 
a new and exciting therapeutic avenue for this group of dis-
orders. Snowden and colleagues have reported an increased 
occurrence of PNFA variant of progressive aphasia associated 
with mutations of this gene (Snowden et al 2006). Josephs 
et al (2007) have also noted more frequent language impair-
ment in patients with FTLD-U associated with this mutation 
than patients without. These patients carried an initial diag-
nosis of PPA and developed early mutism.
Although the actual gene mutations have not yet been 
described, other families with related clinical disorders 
demonstrate linkage to different regions of chromosome 3 Neuropsychiatric Disease and Treatment 2007:3(6) 750
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(Brown et al 1995, 2004; Gydesen et al 2002) and 9 (Hosler 
et al 2000; Kovach et al 2001; Morita et al 2006).
In most families described above, the PPA is either quickly 
followed by the appearance of deﬁ  cits in other cognitive 
domains, or other affected family members do not have 
“typical” PPA, and do not strictly meet the criteria of Weintraub 
et al (1990) and Mesulam (2001). However, Krefft and 
colleagues (2003) describe a family in which all three affected 
siblings meet Mesulam’s more stringent criteria. The genetic 
basis for this kindred, and another in which the affected siblings 
also meet these criteria, have recently been shown to be a result 
of two new PRGN mutations (Mesulam et al 2007).
Risk factors
Certain genetic risk factors have also been noted. These 
include heterozygocity for codon 129 of the prion protein 
(Li et al 2005), presence of the tau H1/H1 genotype, also 
found to be associated with PSP and CBD (Li et al 2005), and 
ApoE ε2-ε4 hereozygocity (Acciarri et al 2006). Vasectomy 
may also increase the risk of developing PPA (Weintraub 
et al 2006). The exact mechanism for this remains unknown, 
but may involve a vasectomy induced immune response to 
sperm that share antigenic epitopes with brain.
Treatment
Treatment of PPA should be considered along at least three 
different avenues: (1) pharmacologic treatments to address 
associated symptoms and potentially slow or stop progression, 
(2) non-pharmacologic interventions to help maintain indepen-
dent function and compensate for growing language deﬁ  cits, and 
(3) support and education of patients and their care givers.
Because of the uncommon nature of PPA, there have been 
no large-scale clinical trials using any known pharmacologic 
agents. The only published therapy trial in PPA is that of 
Reed and colleagues (2004), who could not demonstrate a 
beneﬁ  t of the dopamine agonist bromocriptine in their small, 
randomized, placebo-controlled trial.
A few clinical trials, as well as prospective and retrospective 
case series have been published using various pharmacological 
agents in patients with FTD (Chow 2005; Huey et al 2006; 
Freedman 2007). Conclusions from these studies become 
more relevant to PPA as the disorder progresses and behavioral 
manifestations become more prominent. The use of antidepres-
sants such as trazadone seem to help stabilize the behavioral 
symptoms, but, unfortunately, without an impact on cognition 
(Lebert et al 2004). Similar beneﬁ  ts have been found with the 
cholinesterase inhibitor rivastigmine (Moretti et al 2004), and 
the MAO-B inhibitor selegiline (Moretti et al 2002).
In a novel application of a research tool that is ﬁ  nding 
more frequent use in neurological and psychiatric disorders, 
Finocchiaro and colleagues (2006) have demonstrated that 
high-frequency repetitive transcranial magnetic stimulation 
(hf-rTMS) applied to the left prefrontal cortex produces 
a signiﬁ  cant and lasting improvement on language tasks, 
including verb production. The exact mechanism of such 
an improvement remains unknown, but it is believed that 
hf-rTMS may strengthen neural connection in those areas 
weakened by the disease process.
As has been demonstrated by Medina and Weintraub 
(in press), the frustration of progressive language deﬁ  cits, 
particularly when insight is preserved, can lead to depressed 
mood. Evaluation and treatment of depression with routine 
antidepressants is indicated.
Disease modifying agents are not yet commercially 
available, but potential application of tau reducing drugs 
presently being developed for Alzheimer’s disease may 
prove beneﬁ  cial in PPA patients with tau-based disease 
(Klafki et al 2006). When these become available, the need 
to distinguish tau from non-tau based disease during life will 
become important, and may be aided by genetic analysis, 
new PET imaging ligands (Small et al 2004, 2006), and 
cerebrospinal ﬂ  uid tau species and levels (Hampel and Teipel 
2004). Once the neuropathological mechanism involved in 
null progranulin-mutation based disease is better understood, 
these patients will likely beneﬁ  t from some form of replace-
ment therapy.
The frustration and helplessness experienced by family 
and caregivers should not be overlooked. Counseling 
and education are key. Although families can ﬁ  nd much 
information on the FTD website (http://www.ftd-picks.org) 
and books (Radin et al 2004), some centers have developed 
education and support seminars series that have been received 
very positively (Diehl et al 2003; Banks et al 2006).
Finally, notwithstanding the progressive nature of PPA, 
there remains a role for regular speech therapy assessments, 
which can identify the impact of particular language deﬁ  cits 
on day-to-day function, and help with the implementation 
of evolving communication strategies to help compensate 
(Snowden et al 1995; Graham et al 1999; Galton et al 2001; 
Jokel et al 2002, 2006). The detection of swallowing dif-
ﬁ  culties is also important as appropriate changes in diet and 
feeding habits could be lifesaving.
Conclusion
Since its original description by Mesulam in 1982, our under-
standing of the clinical evolution and neuropatholgic and genetic Neuropsychiatric Disease and Treatment 2007:3(6) 751
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basis of PPA has progressed steadily. PPA should be considered 
in the differential diagnosis of dementias presenting with lan-
guage dysfunction. It can be differentiated from PRAD and FTD 
by the initial absence of signiﬁ  cant memory loss or behavioral 
changes, and the preservation of activities of daily living.
There exists presently no effective treatment for this 
condition, although addressing mood and behavioral issues, 
as well as helping caregivers better understand the disease 
is useful. As the mechanisms leading to the related diseases 
FTD, CBD, and ALS are unraveled, and pathology targeted 
therapy is developed, the future is more promising.
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